Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17399555 | 0.90 | PDK2 (0.35) | MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17399556 | 0.88 | PDK2 (0.37) | MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12302214 | 0.84 | SMN1; SMN2 (0.42) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17399559 | 0.84 | MEN1 (0.35) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13234516 | 0.83 | MAOB (0.41) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9976333 | 0.83 | SMN1; SMN2 (0.34) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16093539 | 0.82 | CA12 (0.39) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21648614 | 0.78 | CASP3 (0.35) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15942835 | 0.78 | TSHR (0.41) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21648585 | 0.77 | CA12 (0.34) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11162952-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210072251-A9 | SINGLE MOLECULE PEPTIDE SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-03-11 | — | — | US | disclosed |
| US-20200124613-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | UNIV TEXAS (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162952-B2 | Single molecule peptide sequencing | MICA, ANPEP, VIP | MEN1 2441/4885KMT2A 1930/4885KDM4E 4067/4885 |
| US-20210072251-A9 | SINGLE MOLECULE PEPTIDE SEQUENCING | QPCTL, VIP, ANPEP | MEN1 2287/4885KMT2A 230/4885KDM4E 751/4885 |
| US-20200124613-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | QPCTL, VIP, ANPEP | MEN1 2287/4885KMT2A 230/4885KDM4E 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.